Atyr Pharma Inc (ATYR) — SEC Filings
Atyr Pharma Inc (ATYR) — 26 SEC filings. Latest: 8-K (Dec 5, 2025). Includes 7 8-K, 6 10-Q, 6 SC 13G/A.
View Atyr Pharma Inc on SEC EDGAR
Overview
Atyr Pharma Inc (ATYR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 5, 2025: Atyr Pharma, Inc. announced on December 4, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing requirements. The company is currently evaluating its options and plans to respond to the notice.
Sentiment Summary
Across 26 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 21 neutral. The dominant filing sentiment for Atyr Pharma Inc is neutral.
Filing Type Overview
Atyr Pharma Inc (ATYR) has filed 7 8-K, 6 10-Q, 1 8-K/A, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (26)
Risk Profile
Risk Assessment: Of ATYR's 19 recent filings, 3 were flagged as high-risk, 10 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $190K |
| Net Income | -$60.2M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $92.9M |
| Operating Margin | N/A |
| Total Assets | $106.7M |
| Total Debt | N/A |
Key Executives
- Jill M. Broadfoot
- Nancy E. Denyes
- Dr. Steven M. Altschuler
- Dr. David J. Earp
- Abigail P. Johnson
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like aTYR PHARMA INC operate in a competitive landscape where success is driven by innovation, clinical trial outcomes, and the ability to secure substantial funding to advance drug candidates through development and commercialization.
Top Tags
biotech (5) · Biotechnology (4) · financials (4) · 10-Q (4) · amendment (3) · institutional-ownership (3) · Clinical Stage (2) · Net Loss (2) · R&D Expenses (2) · ATM Offering (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Consolidated Net Loss | $60.2M | for the nine months ended September 30, 2025, up from $49.1M in 2024 |
| Accumulated Deficit | $592.2M | as of September 30, 2025 |
| Net Proceeds from ATM Offerings | $66.4M | raised during the nine months ended September 30, 2025 |
| Shares Sold via ATM | 13,887,177 | during the nine months ended September 30, 2025 |
| Weighted-Average Price per Share | $4.94 | for ATM offerings during the nine months ended September 30, 2025 |
| Total Cash, Equivalents, and Investments | $92.9M | as of September 30, 2025, expected to fund operations for at least one year |
| Research and Development Expenses | $49.3M | for the nine months ended September 30, 2025, up from $42.1M in 2024 |
| License and Collaboration Revenue | $190K | for the nine months ended September 30, 2025, down from $235K in 2024 |
| Common Shares Outstanding | 97,986,634 | as of October 31, 2025 |
| Net Loss | $14.5 million | for the three months ended June 30, 2025, an increase from $14.3 million in Q2 2024. |
| Cash, Cash Equivalents, and Investments | $60.5 million | as of June 30, 2025, down from $75.0 million at December 31, 2024. |
| Gross Proceeds from ATM Offering | $2.1 million | from July 1, 2025, to August 6, 2025, through Jefferies LLC. |
| Shares Sold in ATM Offering | 1,077,000 | between July 1, 2025, and August 6, 2025. |
| Fiscal Year for Compensation Data | 2024 | Executive compensation details pertain to this year. |
| Prior Fiscal Year for Comparison | 2023 | Used for comparative analysis of compensation trends. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant stake in aTyr Pharma Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"The substantial institutional ownership by FMR LLC could attract other institutional investors to aTyr Pharma Inc.","entity":"aTyr Pharma Inc.","targetDate":"2024-08-09","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Atyr Pharma Inc (ATYR)?
Atyr Pharma Inc has 26 recent SEC filings from Jan 2024 to Dec 2025, including 7 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ATYR filings?
Across 26 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 21 neutral. The dominant sentiment is neutral.
Where can I find Atyr Pharma Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Atyr Pharma Inc (ATYR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Atyr Pharma Inc?
Key financial highlights from Atyr Pharma Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ATYR?
The investment thesis for ATYR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Atyr Pharma Inc?
Key executives identified across Atyr Pharma Inc's filings include Jill M. Broadfoot, Nancy E. Denyes, Dr. Steven M. Altschuler, Dr. David J. Earp, Abigail P. Johnson.
What are the main risk factors for Atyr Pharma Inc stock?
Of ATYR's 19 assessed filings, 3 were flagged high-risk, 10 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Atyr Pharma Inc?
Recent forward-looking statements from Atyr Pharma Inc include guidance on {"claim":"FMR LLC will maintain a significant stake in aTyr Pharma Inc. for the foreseeable future.","entity":"FMR LLC", and 1 other predictions.